Stock Ratings / Health Care / LTRN / financials

LSTA (32) TPST (44) GDTC (54) TVRD (40) ⌘ Pro Terminal →

Lantern Pharma Inc. (LTRN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is Lantern Pharma Inc. (LTRN)?

In FY 2025 (10-K), LTRN converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$0.73 -5.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Lantern Pharma Inc. (LTRN) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $10.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LTRN)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How LTRN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.4%	-$17.1M	-$15.7M	-45%
FY 2024	$4.00B	52%	-0.6%	-$20.8M	-$17.8M	-45%
FY 2023	$4.00B	52%	-0.4%	-$16.0M	-$14.3M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LTRN)

✓Walkthrough of LTRN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LTRN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -64.39%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.72H $0.74L $0.63C $0.73VOL 218.5K

RES: $1.08SUP: $0.43SMA50: $1.30SMA200: $2.46

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LTRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LTRN Butterfly Map → + Track LTRN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LTRN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LTRN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LTRN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LTRN)

Health Care Rank #593 of 1016 ⚔️ LSTA vs LTRN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LTRN vs. LSTA, TPST, GDTC, TVRD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lantern Pharma Inc. (LTRN) ranks #593 by composite RQD confidence (42/100, grade D-) and #889 by equity capitalization ($10.9M). Within this direct 5-issuer industry benchmark cohort, LTRN leads on earnings valuation at N/A trailing P/E, while LTRN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GDTC currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with LTRN at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LTRN ACTIVE Lantern Pharma Inc.	D-	42/100	—	—	-35.0%	-5.52%	$10.9M	Benchmark Subject
LSTA Lisata Therapeutics Inc.	E	32/100	—	—	-35.0%	-4.72%	$10.9M	/lsta-vs-ltrn →
TPST Tempest Therapeutics Inc.	D	44/100	—	—	-35.0%	-1.24%	$10.7M	/tpst-vs-ltrn →
GDTC CytoMed Therapeutics Limited	D+	54/100	—	—	—	-3.68%	$10.7M	/gdtc-vs-ltrn →
TVRD Tvardi Therapeutics Inc.	D-	40/100	—	—	-35.0%	-2.73%	$11.5M	/tvrd-vs-ltrn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001763950

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lantern Pharma Inc. (LTRN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$17.1M, operating cash flow of -$15.7M, and free cash flow of -$15.7M (+12.0% YoY). On the balance sheet, LTRN closed FY2025 with $11.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$17.1M	-$15.7M	-$15.7M	$11.0M	—
FY2024 (FY)	2024-12-31	$0	-$20.8M	-$17.8M	-$17.8M	$25.6M	—
FY2023 (FY)	2023-12-31	$0	-$16.0M	-$14.3M	-$14.3M	—	—

3. LTRN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LTRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lantern Pharma Inc. (NASDAQ: LTRN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.73 (-5.52% 1D, market cap $10.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LTRN ranks #593 in composite RQD confidence.

How does LTRN compare to LSTA and TPST in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LTRN carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LSTA (Lisata Therapeutics Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $10.9M) and TPST (Tempest Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $10.7M). Among the 5-stock peer group, LTRN leads on earnings multiple (N/A) while LTRN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LTRN?

Per LTRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001763950), Lantern Pharma Inc. generated $0 in revenue, -$17.1M in net income, and -$15.7M in free cash flow against $11.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LTRN trading relative to its 50-day, 200-day, and 52-week technical levels?

LTRN last traded at $0.73 (-5.52% on volume of 233,913 shares), positioning the stock -43.85% below its 50-day simple moving average ($1.30) and -70.33% below its 200-day simple moving average ($2.46). Across its 52-week range of $0.59 to $4.34, LTRN sits at the 3.7% percentile with a 14-day RSI of 31.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.82).